Do fumonisins inhibit ceramide synthase and cause liver toxicity?

Fumonisins are toxic metabolites produced by Fusarium fungi, commonly found in corn-based crops. Scientific research consistently identifies these mycotoxins as potent disruptors of cellular homeostasis, primarily through the inhibition of key enzymes involved in lipid signaling and structural integrity.

Mechanistic disruption of sphingolipid metabolism

The primary mechanism of action for fumonisin B1 (FB1) is the competitive inhibition of ceramide synthase (CerS). Because FB1 structurally mimics sphingoid bases like sphinganine (Sa) and sphingosine (So), it binds to the enzyme’s active site and undergoes N-acylation, effectively freezing and inactivating CerS.

• Metabolic imbalance: This inhibition prevents the conversion of Sa and So into ceramides, leading to a massive accumulation of free sphinganine.
• Biomarkers: A significantly elevated Sa:So ratio in serum or urine serves as a reliable biomarker for fumonisin exposure across species.
• Complex lipid depletion: The resulting shortage of downstream sphingolipids, such as sphingomyelin and glycosphingolipids, impairs membrane stability and vital signal transduction pathways.

Oxidative stress and inflammatory signaling

The accumulation of free sphingoid bases and the depletion of ceramides trigger a cascade of cellular stress.

• ROS generation: Excess sphinganine induces mitochondrial dysfunction and the overproduction of reactive oxygen species (ROS), leading to lipid peroxidation.
• Inflammatory pathways: Oxidative stress activates the NF-κB transcription factor, which upregulates pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. This creates a feedback loop of inflammation and cellular injury, particularly within hepatic tissues.

Liver toxicity and clinical implications

The liver is a critical target organ for fumonisin-induced damage.

• Animal evidence: Toxicological bioassays in rodents and swine demonstrate dose-dependent hepatotoxicity, characterized by elevated liver enzymes (ALT/AST), hepatocyte apoptosis, and, in chronic cases, hepatocellular carcinoma.
• Human health: While human epidemiological data primarily link high dietary exposure to esophageal cancer, the shared mechanistic pathways observed in human cell lines (like HepG2) indicate a significant potential for liver injury. For a 61-year-old female, the risk of hepatotoxicity would likely be exacerbated by any underlying liver conditions or concurrent metabolic stressors.

Bottom line

The claim is strongly supported by mechanistic and toxicological evidence. Fumonisins disrupt sphingolipid metabolism via CerS inhibition, driving oxidative stress and inflammation that lead to significant liver toxicity in mammalian models.